Abstract |
In this study, it has been shown that in 21 patients with AML the dCyd kinase and dCyd deaminase activities correspond closely to the clinical response to ara-C remission induction therapy. Patients with primary disease were treated with a conventional-dose ara-C regimen whereas nonresponders and relapsed patients followed an ID ara-C regimen (1 g/m2 X 12). Of these 21 patients (11 with primary disease and ten relapsed), seven had ara-C resistant disease (three primary and four relapsed patients). Five of the seven patients had a very low dCyd kinase and normal dCyd deaminase activity, whereas the other two had a normal dCyd kinase and an increased dCyd deaminase activity.
|
Authors | L P Colly, W G Peters, D Richel, M W Arentsen-Honders, C W Starrenburg, R Willemze |
Journal | Seminars in oncology
(Semin Oncol)
Vol. 14
Issue 2 Suppl 1
Pg. 257-61
(Jun 1987)
ISSN: 0093-7754 [Print] United States |
PMID | 3035720
(Publication Type: Journal Article)
|
Chemical References |
- Cytarabine
- Phosphotransferases
- Deoxycytidine Kinase
- Nucleoside Deaminases
- Cytidine Deaminase
- deoxycytidine deaminase
|
Topics |
- Adolescent
- Adult
- Age Factors
- Cytarabine
(therapeutic use)
- Cytidine Deaminase
- Deoxycytidine Kinase
(metabolism)
- Humans
- Leukemia, Myeloid, Acute
(drug therapy, enzymology)
- Middle Aged
- Nucleoside Deaminases
(metabolism)
- Phosphotransferases
(metabolism)
|